Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Kintsugi
AddedFeb 15, 2024
UpdatedJun 23, 2026
Kintsugi

Kintsugi

Closed

Kintsugi: Award-winning AI software detecting depression and anxiety through voice biomarkers.

HQ
Berkeley, CA, US
Founded
2019
Accelerator
Techstars logoTechstars: UnitedHealthcare2020
Overview
Analysis
Compare
Fundraising
Employees
News

Kintsugi, founded with the mission to bridge the mental health care gap, develops innovative voice biomarker software designed to detect signs of depression and anxiety from short clips of free-form speech. Their core vision is to provide accessible and non-invasive mental health diagnostics through advanced AI technology. The company offers products such as Kintsugi Voice and Kintsugi Connect, which integrate seamlessly into existing healthcare systems to enhance mental health assessments. Their market focus spans healthcare providers, insurers, and digital health platforms.

Notable figures associated with Kintsugi include its founders and a team of experts in AI and mental health. The company has garnered significant recognition, including being named one of Forbes' Top 50 AI companies to watch in 2022 and making the Fierce 15 list in 2023. These accolades underscore Kintsugi's impact on the mental health sector by providing cutting-edge tools that improve early detection and intervention for mental health conditions.

Kintsugi - Products & Services

  • Kintsugi Voice logo

    Kintsugi Voice

    Kintsugi Voice detects depression and anxiety from speech using AI biomarkers.

    Competing Products

    Canary Speech logo
    Ellipsis Health logo
    Sonde Health logo
    Sonde Health logo
    Cognition logo
  • Kintsugi Connect logo

    Kintsugi Connect

    Kintsugi Connect integrates voice biomarker screening into healthcare workflows.

Kintsugi - Similar Companies

Cognition logo

Cognition

cognition.us

Canary Speech logo

Canary Speech

canaryspeech.com

Sonde Health logo

Sonde Health

sondehealth.com

Ellipsis Health logo

Ellipsis Health

ellipsishealth.com

Kintsugi - Quick Facts

Who are Kintsugi's competitors?

Companies similar to Kintsugi include Cognition, Canary Speech, Sonde Health and Ellipsis Health.

When was Kintsugi founded?

Kintsugi was founded in 2019.

Where is Kintsugi's headquarters located?

Kintsugi's headquarters is located in Berkeley, CA, US.

When was Kintsugi's last funding round?

Kintsugi's most recent funding round was for $20M (USD) in February 2022.

How much has Kintsugi raised to-date?

As of Feb 28, 2022, Kintsugi has raised a total of $30.9M (USD).

Kintsugi - Classification

Ownership
  • Venture Capital
Technology
  • AI
  • Machine Learning
Geographic Exposure
  • Global
Model
  • Platform
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Tags
  • AI Operations
  • Healthcare
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software